Drugs / VX-993
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT06886269 | Mar → May 2025 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT06523595 | Jul → Dec 2024 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT06508762 | Jul → Sep 2024 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT06420765 | May 2024 → Mar 2025 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT06394167 | May 2024 → Feb 2025 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT06392659 | May → Jul 2024 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT06226454 | Jan → Jun 2024 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT05653323 | Dec 2022 → Sep 2023 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT06619847 | Oct 2024 → May 2025 | — | Vertex Pharmaceuticals Incorporated | Completed | Missed primary |
| Phase 2 | NCT06619860 | Oct 2024 → Mar 2027 expected | diabetic neuropathy | Vertex Pharmaceuticals Incorporated | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-08-04 | Vertex Pharmaceuticals Incorporated | Results Vertex Reports Second Quarter 2025 Financial Results vrtx.com ↗
Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted sum of the pain intensity difference from 0 to 48 hours (SPID48) compared to placebo. |
| 2025-08-04 | Vertex Pharmaceuticals Incorporated | Results Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain vrtx.com ↗
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-04 | Vertex Pharmaceuticals Incorporated | Vertex Reports Second Quarter 2025 Financial Results vrtx.com ↗ |
| 2025-08-04 | Vertex Pharmaceuticals Incorporated | Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain vrtx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VX-993 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06226454 ↗ |
| Action | Inhibit | “NaV1.8 inhibition” NCT06420765 ↗ |
| Route | Oral | “Suspension for oral administration.” NCT05653323 ↗ |